Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer
Cancer Treatment and Research Communications · 2023
DOI: 10.1016/j.ctarc.2023.100741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Treatment and Research Communications, 2023. Verfasst von Anshul Gupta und 5 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences (AIIMS), New Delhi, India. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: All-India Institute of Medical Sciences.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- All India Institute of Medical Sciences (AIIMS), New Delhi, India.
- All India Institute of Medical Sciences (AIIMS), New Delhi, India. Electronic address: ajaygogia@gmail.com.
- National Cancer Institute, Jhajjar, Haryana, India.
Förderung
- All-India Institute of Medical Sciences
Zitieren
APA
Gupta, A., Gogia, A., Deo, S., Sharma, D. N., Mathur, S., & Sagiraju, H. K. R. (2023). Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2023.100741
Vancouver
Gupta A, Gogia A, Deo S, Sharma DN, Mathur S, Sagiraju HKR. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer. Cancer Treatment and Research Communications. 2023. doi:10.1016/j.ctarc.2023.100741
BibTeX
@article{Gupta2023,
author = {Gupta, Anshul and Gogia, Ajay and Deo, Svs and Sharma, D N and Mathur, Sandip and Sagiraju, Hari Krishna Raju},
title = {Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer},
journal = {Cancer Treatment and Research Communications},
year = {2023},
doi = {10.1016/j.ctarc.2023.100741}
}
EUVIMED